Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/300,713external-prioritypatent/US5582591A/en
Application filed by Delabar Co LtdfiledCriticalDelabar Co Ltd
Application grantedgrantedCritical
Publication of TW357092BpublicationCriticalpatent/TW357092B/en
A sort of water-free solid medicament component, used on patients for immediate diffusion of medicament not through the intestine, having the component at least one medicine and a pharmaceutically acceptable carrier of close to 50 wt.%, where the medicament and the carrier are properly selected and prepared, for the medicine being diffused from the component by contact of non-intestine organism and, based on a blood level curve of a medicine, distribute into the blood of the patient, being the curve injected by means of liquid composition into the medicine for the blood level curve.
TW084109203A1994-09-021995-09-02Transport of solid medicament components
TW357092B
(en)
Use of N-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
Interferon may offer first drug therapy for diabetic retinopathy. New research showing that alpha-interferon blocks new blood vessel formation in the iris of monkeys may point the way to new treatment for diabetes retinopathy